Skip to main content
Advertisement
Advertisement
ALZN
ALZN logo
Alzamend Neuro, Inc. Common Stock
1.41
USD
Sponsored
-0.14
-9.03%
Nov 06, 15:58 UTC -5
Closed
exchange

After-Market

1.47

+0.06
+4.54%

Alzamend Neuro, Inc. Common Stock (ALZN) Earnings

ALZN Earnings Reports

Positive Surprise Ratio

ALZN beat 10 of 19 last estimates.

53%

Next Report

Date of Next Report
Dec 07, 2026
Estimate for Q2 27 (Revenue/ EPS)
--
/
-$0.23
Implied change from Q1 27 (Revenue/ EPS)
--
/
-66.18%
Implied change from Q2 26 (Revenue/ EPS)
--
/
-23.33%

Alzamend Neuro, Inc. Common Stock earnings per share and revenue

On Sep 10, 2026, ALZN reported earnings of -0.68 USD per share (EPS) for Q1 27, missing the estimate of -0.57 USD, resulting in a -19.05% surprise. Revenue reached --, compared to an expected --, with a 0.00% difference. The market reacted with a +1.18% price change (close before vs. close after earnings).
Looking ahead to Q2 27, 4 analysts forecast an EPS of -0.23 USD, with revenue projected to reach -- USD, implying an decrease of -66.18% EPS, and increase of 0.00% in Revenue from the last quarter.

Industry Peers’ Earnings

Industry Peers' Earnings displays EPS earnings data from companies in the same industry. Click on a card to view more details.

logo
Moderna, Inc. Common Stock
Report Date
Nov 06, 2026 For Q3 26
Estimate
-$1.27
Actual
$0.38
Surprise
+129.79%
logo
Zai Lab Limited - ADR
Report Date
Nov 05, 2026 For Q3 26
Estimate
-$0.05
Actual
-$0.41
Surprise
-637.41%
logo
Intellia Therapeutics, Inc
Report Date
Nov 05, 2026 For Q3 26
Estimate
-$0.81
Actual
-$0.91
Surprise
-11.97%
logo
Eton Pharmaceutcials, Inc. Common Stock
Report Date
Nov 05, 2026 For Q3 26
Estimate
$0.31
Actual
$1.06
Surprise
+232.50%
logo
Castle Biosciences, Inc. Common Stock
Report Date
Nov 05, 2026 For Q3 26
Estimate
-$0.37
Actual
-$0.13
Surprise
+65.32%
logo
Starling Oncology, Inc. Common Stock
Report Date
Nov 05, 2026 For Q3 26
Estimate
-$0.04
Actual
-$0.13
Surprise
-165.31%
logo
Allogene Therapeutics, Inc. Common Stock
Report Date
Nov 05, 2026 For Q3 26
Estimate
-$0.15
Actual
-$0.15
Surprise
+0.33%
logo
Tectonic Therapeutic, Inc. Common Stock
Report Date
Nov 05, 2026 For Q3 26
Estimate
-$1.35
Actual
-$1.08
Surprise
+20.37%
logo
SAB Biotherapeutics, Inc. Common Stock
Report Date
Nov 05, 2026 For Q3 26
Estimate
-$0.27
Actual
-$0.24
Surprise
+12.85%
logo
Anika Therapeutics Inc
Report Date
Nov 06, 2026 For Q3 26
Estimate
$0.06
Actual
$0.28
Surprise
+373.86%
FAQ
For Q1 2027, Alzamend Neuro, Inc. Common Stock reported EPS of -$0.68, missing estimates by -19.05%, and revenue of $0.00, 0% as expectations.
The stock price moved up 1.18%, changed from $1.70 before the earnings release to $1.72 the day after.
The next earning report is scheduled for Dec 07, 2026.
Based on 4 analysts, Alzamend Neuro, Inc. Common Stock is expected to report EPS of -$0.23 and revenue of -- for Q2 2027.
Check FXEmpire's Earnings Calendar for today's list of reporting companies.
Advertisement